Urinary Metabolites as Biomarkers of Early Radiation Cystitis in Patients With Prostate Cancer Undergoing Radiotherapy.

BACKGROUND/AIM: Treatment-related bladder toxicities are a primary concern in the management of prostate cancer radiotherapy. This study aimed to identify urinary metabolites that can predict early radiation cystitis-related toxicities in patients undergoing radiotherapy for prostate cancer.

PATIENTS AND

METHODS

Patients' clinical characteristics and urine samples were collected before, two weeks after, at the end, and three months after the initiation of radiotherapy and subsequently analyzed. Capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry were used for comprehensive quantification of urinary metabolites. Multivariate analysis was conducted to identify potential protective factors against the early toxicities of radiation cystitis.

RESULTS

A total of 176 samples were obtained from 44 patients. Betaine, tartrate, N,N-dimethylglycine, and homocarnosine were identified as independent protective factors against early toxicities of radiation cystitis among various potential confounding metabolic factors. Comorbid diabetes mellitus was also identified as a protective factor.

CONCLUSION

Betaine, tartrate, N,N-dimethylglycine, and homocarnosine were identified as protective urinary metabolites against early radiation cystitis. Urinary metabolomic profiling may be a useful tool for investigating disease metabolism in metabolic disorders and cancers. Its ease of use and repeatability make it an optimal method for patient follow-up.